A Phase II Clinical Trial of Nedaplatin and Amurubicin Therapy for Advanced and Recurrent Squamous Cell Lung Cancer.

Phase 2

• Conditions: squamous cell Lung carcinoma

• Registration Number: JPRN-UMIN000007587
• Lead Sponsor: agasaki Thoracic Oncology Group

Brief Summary

Partial response was observed in seven of 21 cases (ORR, 33.3%; 95% confidence interval [CI], 14.5-52.2). Disease control rate, which includes stable disease, was 71.4%. Median OS and PFS was 14.6 and 4.1 months, respectively.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-03-27
• Study Completion: 2018-05-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 21

Inclusion Criteria

Not provided

Exclusion Criteria

1)Symptomatic or apparent interstitial pneumonia/lung fibrosis on X-ray image findings. 2)Patients wth uncontrollable fever. 3)Severe complications, such as cardiac. failure, uncontrollable diabetic or hypertension. 4)uncontrollable pleural effusion, pericardial effusionor ascites. 5)Active concomitant malignancy. 6)Severe drug allergies or history of drug hypersensitivity. 7)With active infection. 8)mental disorder. 9)Pregnant, lactating or women of child-bearing potential. 10)The case that is judged to be inadequacy for this study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified